Norway Wealth Fund Sits Out Novo Nordisk Board Vote as Pfizer Wins Metsera Bid

Norway's sovereign wealth fund has chosen to abstain from voting on the board members election at Novo Nordisk (NASDAQ: NVO)'s upcoming extraordinary shareholders' meeting scheduled for November 14. This move comes amid significant upheaval in the Danish pharma giant's leadership, with the current chair and six independent directors set to step down.

The shake-up stems from tensions between the outgoing board and the Novo Nordisk Foundation-the controlling shareholder that holds the majority of voting rights through Novo Holdings. The foundation has criticized the board for slow reactions to market challenges in the U.S. and reluctance to overhaul management. It intends to install Lars Rebien Sørensen as the new board chair, a figure with close ties to the foundation.

Despite the foundation's strong stance, the Norwegian fund did not provide a reason for abstaining from the vote. Meanwhile, Sørensen emphasized the goal isn't a "coup" but rather to sharpen Novo's competitive edge, especially in the U.S. market where it faces a "transactional" business environment. New CEO Mike Doustdar, who took helm in August, has already embarked on job cuts and a strategic refocus.

Ruffling the waters further, shares of Novo Nordisk climbed more than 3% in early trading following the company's decision to withdraw its takeover offer for Metsera, a U.S.-based weight-loss drug developer. The $10 billion acquisition was snapped up by Pfizer (NYSE: PFE), handing the pharmaceutical giant a solid foothold in the fast-expanding obesity treatment market.

Metsera had initially labeled Novo's bid as attractive but accepted Pfizer's higher offer due to concerns over antitrust issues related to Novo's proposal. Novo confirmed its exit from the bidding war over the weekend, conceding the race to Pfizer.

Pfizer's acquisition bankrolls potential future earnings, with Metsera's pipeline still years away from market approval. This deal marks a notable step for Pfizer as it expands beyond its traditional portfolios into high-growth therapeutic areas.

For Novo Nordisk, the missed chance to acquire Metsera comes during a period of internal change and external pressure. CEO Doustdar's challenge now includes regaining momentum in the obesity drug sector and managing shareholder conflicts that have split the company's leadership.

The Norwegian wealth fund's decision to abstain from the board vote leaves questions about the level of international investor confidence amid the governance turbulence. With the leadership transition and the setback in acquiring Metsera, Novo Nordisk is navigating choppy waters that could reshape its strategic positioning in the years ahead.